References
- Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28:3167-75; PMID:20516446; http://dx.doi.org/10.1200/JCO.2009.26.7609
- Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
- Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1. Clin Can Res 2014; 20:5064-74. [ Epub ahead of print]; PMID:24714771
- Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4:127ra37; PMID:22461641; http://dx.doi.org/10.1126/scitranslmed.3003689
- Grosso J, Horak C, Inzunza D, Cardona D, Simon J, Gupta A, Sankar, V, Park JS, Kollia G, Taube JM et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients with advanced solid tumors treated with nivolumab. J Clin Oncol 2013; 31 (suppl):Abstr nr 3016
- Daud HI, Hamid O, Ribas A, Hodi FS, Hwu, WJ, Kefford R, Wolchok J, Hersey P, Weber JS, Joseph R, et al. Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma: correlation of tumor PD-L1 expression with outcome. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5.9; San Diego, CA. Philadelphia (PA): AACR; 2014. Abstract nr CT104
- Gandhi L, Balmanoukian A, Hui R, Hamid O, Rizvi NA, Leigh N, Gubens M, Goldman JW, Lubiniecki GM, Emancipator K et al. MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer (NSCLC): antitumor activity and association with tumor PD-L1 expression. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5.9; San Diego, CA. Philadelphia (PA): AACR; 2014. Abstract nr CT105
- Gettinger SN, Shepherd FA, Antonia SJ, Brahmer JR, Chow LQM, Juergens RA, Borghaei H, Shen Y, Harbison C, Alaparthy S et al. First line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: safety, efficacy, and correlation of outcomes with PD-L1 Status. J Clin Oncol 2014; 32(suppl):8024